Michael Schöll, PhD, University of Gothenburg, Gothenburg, Sweden, comments on the wealth of ongoing research into phosphorylated tau (p-tau) as a biomarker for Alzheimer’s disease diagnosis, prognostication, and monitoring. Extensive efforts are underway to fully characterize several p-tau species and how they change over time and in response to comorbidities. P-tau can be measured in plasma and seems to reflect cognitive impairment and cerebral amyloid burden more strongly than Aβ biomarkers. Additionally, evidence has shown that changes in p-tau can be detected very early in the disease course and continue to increase as amyloid burden increases, making it a promising marker for early intervention trials. Further insights into the impact of the assay used, biological factors, and analytical variation are needed to progress these biomarkers. This interview took place at the Alzheimer’s Research UK (ARUK) Conference 2023 in Aberdeen, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
